Public Health & Policy
FDA General
- By the Numbers
- Clinical Trials
- Environmental Health
- Equity in Medicine
- Ethics
- FDA General
- General Professional Issues
- Health Policy
- Medicaid
- Medical Education
- Medicare
- Military Medicine
- Opioids
- Practice Management
- Product Alert
- Public Health
- Repeal and Replace
- Stem Cell Research
- Washington Watch
- Work Force
More in FDA General
Broad indication doubles the number of patients eligible for adjuvant CDK4/6 inhibition
Sep 17, 2024
38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks
Sep 13, 2024
Agency advisors put their foot down on shaky science for Ocaliva in primary biliary cholangitis
Sep 13, 2024